10% Tumor Diameter Shrinkage on the First Follow-Up Computed Tomography Predicts Clinical Outcome in Patients With Advanced Renal Cell Carcinoma Treated With Angiogenesis Inhibitors: A Follow-Up Validation Study

BACKGROUND. Vascular endothelial growth factor (VEGF)-targeted agents are standard therapies for metastatic renal cell carcinoma (mRCC), associated with variable tumor shrinkage. Response Evaluation Criteria in Solid Tumors (RECIST) is of limited utility in this setting, and other imaging changes ar...

Full description

Saved in:

Bibliographic Details
Main Authors:	Krajewski, Katherine M., Franchetti, Yoko, Nishino, Mizuki, Fay, André P., Ramaiya, Nikhil, Van den Abbeele, Annick D., Choueiri, Toni K.
Format:	Artigo
Language:	Inglês
Published:	AlphaMed Press 2014
Subjects:	Genitourinary Cancer: Renal, Bladder, and Testicular
Online Access:	https://ncbi.nlm.nih.gov/pmc/articles/PMC4012965/ https://ncbi.nlm.nih.gov/pubmed/24755461 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2013-0391
Tags:	Add Tag No Tags, Be the first to tag this record!

10% Tumor Diameter Shrinkage on the First Follow-Up Computed Tomography Predicts Clinical Outcome in Patients With Advanced Renal Cell Carcinoma Treated With Angiogenesis Inhibitors: A Follow-Up Validation Study

Similar Items